Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors

Autor: M. Gael, T. Adam, M. Mariano‐Bourin, A.‐C. Bursztejn

Publikováno v: Journal of the European Academy of Dermatology and Venereology. 36:1541-1551

Dupilumab has demonstrated a great reduction in chronic pruritus that is the hallmark of atopic dermatitis (AD). Underscoring relevant pathogenesis similarities emerging from AD, chronic idiopathic pruritus (CIP) and chronic prurigo (CP), several aut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238a12e32696a0aa84d0c364d5de011b
https://doi.org/10.1111/jdv.18221

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant

Autor: M. Lahfa, M. Severino-Freire, F. Aubin, Smail Hadj-Rabia, F. Corgibet, François Maccari, M. Amy de la Bretèque, et le Gem Resopso, Sébastien Barbarot, la Fédération française de formation continue et d’évaluation en dermatologie-vénéréologie, H. Barthelemy, A. Beauchet, Céline Phan, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, M. Ruer-Mulard, F. Boralevi, E. Mahé, A.-C. Bursztejn

Publikováno v: Annales de Dermatologie et de Vénéréologie. 147:429-438

Resume Introduction Le psoriasis touche 0,5 % des enfants en Europe dont 15 a 30 % avec des formes moderees a severes. Peu de medicaments locaux ou systemiques du psoriasis possedent des indications etendues a l’enfant, necessitant l’utilisation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dbbf15e80bb19dcf3db8cee15400b34a
https://doi.org/10.1016/j.annder.2020.01.021

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

Autor: J, Zitouni, A-C, Bursztejn, A, Belloni Fortina, A, Beauchet, V, Di Lernia, A, Lesiak, J, Thomas, Z, Topkarci, N, Murashkin, P, Brzezinski, T, Torres, A, Chiriac, C, Luca, T, McPherson, M, Akinde, A, Maruani, R, Epishev, H, Vidaurri de la Cruz, P C, Luna, M, Amy de la Bretêque, A, Lasek, E, Bourrat, M, Bachelerie, S, Mallet, M, Steff, A, Bellissen, I, Neri, E, Zafiriou, J M P A, van den Reek, E, Sonkoly, S K, Mahil, C H, Smith, C, Flohr, H, Bachelez, E, Mahé

Publikováno v: JEADV : Journal of the European Academy of Dermatology and Venereology, 36, 11, pp. 2076-2086
JEADV : Journal of the European Academy of Dermatology and Venereology, 36, 2076-2086

Contains fulltext : 287330.pdf (Publisher’s version ) (Closed access) BACKGROUND: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::536ac2d1a979b41ec25684a02991dd1f
http://hdl.handle.net/11577/3451361